

Bevacizumab JO25567

### PRELIMINARY SCORE

#### CURATIVE



#### NON-CURATIVE



### ADJUSTMENTS

#### Quality of life



No QoL benefit

#### Serious and disabling adverse effects



#### Other adjustments



Mature data shows no OS advantage and no improved QoL

Bevacizumab JO25567

### FINAL SCORE

#### CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

#### NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

#### INFORMATION

Tumour type: Thoracic Malignancies

Therapeutic Indication: In combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations

Experimental Arm: Bevacizumab + Erlotinib

Control Arm: Erlotinib



